SCHEDULE: Balyasny Asset Management Discloses SAB Biotherapeutics Stake

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5,089,939 shares of SAB Biotherapeutics, Inc. common stock, representing 9.99% of the class.

Summary

• Balyasny Asset Management L.P. (BAM), along with its general partner BAM GP LLC, parent Balyasny Asset Management Holdings LP, and managing member Dmitry Balyasny, have collectively disclosed beneficial ownership of 5,089,939 shares of SAB Biotherapeutics, Inc. common stock.
• This holding represents 9.99% of the total outstanding shares, based on the company's annual report filed on March 9, 2026.
• The reported shares include 3,760,439 directly held shares and 1,329,500 shares issuable upon the exercise of 34,650 warrants.
• These warrants are subject to a 'Beneficial Ownership Limitation' which prevents exercise if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard disclosure of beneficial ownership by an investment firm and does not inherently signal positive or negative performance for the company.

Positives

• Balyasny Asset Management has taken a significant stake, indicating confidence in SAB Biotherapeutics' potential.
• The disclosure confirms a substantial investment by a known asset management firm.

Negatives

• The 'Beneficial Ownership Limitation' on warrants suggests potential complexities or restrictions in fully exercising these rights.

Risks

• The Beneficial Ownership Limitation on warrants could restrict the ability to increase ownership beyond 9.99% without triggering regulatory issues.
• Potential for future sales of shares by Balyasny Asset Management could impact SAB Biotherapeutics' stock price.

Future Outlook

The filing does not contain forward-looking statements or guidance from SAB Biotherapeutics. It solely reports on the beneficial ownership of securities by Balyasny Asset Management.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors acquiring a significant, but typically passive, stake in a company. This filing indicates Balyasny Asset Management's strategic interest in SAB Biotherapeutics, potentially as a long-term investment.

Stakeholder Impact

• Shareholders: The disclosure may influence market perception of SAB Biotherapeutics due to the significant stake held by a known asset manager. It could signal institutional interest.
• Management: The company's management will be aware of Balyasny Asset Management's significant ownership position.

Next Steps

• Balyasny Asset Management will continue to hold and potentially manage its stake in SAB Biotherapeutics.
• SAB Biotherapeutics will continue its operations as disclosed in its other filings.

Key Dates

Keywords

SAB Biotherapeutics, Schedule 13G, Balyasny Asset Management, beneficial ownership, common stock, warrants, investment, SEC filing